45 results about "Serum transaminase" patented technology

The invention relates to human sDR5-Fc recombinant fusion protein and application of the human sDR5-Fc recombinant fusion protein to preparation of medicine for preventing and treating drug induced liver injury. Through long-time study of the inventor, the protein gene sequence is selected again, and the novel human sDR5-Fc recombinant fusion protein provided by the invention is obtained. Through a great number of experiments, the human sDR5-Fc recombinant fusion protein can obviously reduce the serum transaminase level in various mouse drug induced liver injury models; the liver pathologic damage is reduced; the liver cell apoptosis rate is obviously reduced; the mouse survival ratio is improved. The human sDR5-Fc recombinant fusion protein is used as novel candidate medicine for preventing and treating the drug induced liver injury; the treatment range is wide; targets are specific; the action is special and fast; the curative effect is obvious; the safety is high; great development potential is realized.

A Chinese medicine with immune regulation function for treating alcoholic liver cell injury and relative hyper-serum-transaminase contains ganoderic polyose and cordycepic polyose.

The present invention relates to the field of biomedicine. The present invention provides application of a farnesoid X receptor (FXR) expression interference reagent in preparation of anti-hepatic fibrosis drugs. Specifically, the present invention relates to application of FXR for treatment of hepatic fibrosis, by tail intravenous injection of the farnesoid X receptor (FXR) expression interference reagent (namely, an adenovirus carrying FXR plasmid) to mice, the expression level of the FXR in hepatocytes is significantly increased, CCl4-induced hepatic fibrosis can be significantly countered,hepatocyte morphology and structural integrity can be maintained, and serum transaminase level can be reduced. A new approach for clinical treatment of liver diseases especially hepatic fibrosis is provided.

The invention discloses a traditional Chinese medicine composition for preventing and curing hepatic fibrosis, and a preparation method and application thereof. The composition is prepared by taking traditional Chinese medicines, namely angelica, red flower, peach kernel, the root bark of the peony tree, root of common peony, Ligusticum wallichii, the root of three-nerved spicebush, trogopterus dung, corydalis tuber, rhizoma cyperi, fructus aurantii and liquorice, as raw materials according to the weight ratio of 9:9:9:6:6:6:6:9:3:5:5:9. The preparation method of the composition comprises the following steps of: taking the traditional Chinese medicines according to the ratio; decocting by using water for two times, each time for 1 h at the beginning of boiling, wherein the volume of water for the first time is 10 times as much as the total weight of the traditional Chinese medicines; and the volume of water for the second time is 8 times as much as the total weight of the traditional Chinese medicines; and finally, mixing the two kinds of decoction liquid and concentrating. The traditional Chinese medicine composition disclosed by the invention is capable of reducing serum transaminase, lightening liver collagen precipitation degree and improving hepatic inflammatory and fibrosis pathological change, has the function of preventing and curing hepatic fibrosis pathological change, and can be applied to preparing a pharmaceutical preparation for preventing and curing hepatic fibrosis.

The invention discloses a medicine composition with acetylcysteine and medical application of the medicine composition. The medicine composition with acetylcysteine contains clenbuterol hydrochloride and a natural product compound (I) which adopts a novel structure; when acetylcysteine and the compound (I) work independently, the effects of reducing serum transaminase, bilirubin and urea nitrogen contents of liver damaged animals can be achieved, jaundice and renal dysfunction are relieved, and the toxin content of plasma can be reduced; when acetylcysteine and the compound (I) are combined, the pharmacologic action is more obvious, and the medicine composition can be prepared into a medicine for treating acute liver failure; compared with the prior art, the medicine composition disclosed by the invention has outstanding substantive features and a remarkable progress.

The invention provides application of allyl methyl trisulfide in the preparation of a medicine and/or a health product for preventing and/or treating drug-induced liver injury. Allyl methyl trisulfidecan effectively reduce death rate caused by APAP and inhibit rise of serum transaminase activity and increase of liver coefficient due to APAP, and can obviously mitigate liver injury caused by APAP.

The invention relates to nucleic acid constructs and gene therapy vectors that comprise an ATP7B variant for use in the treatment of conditions associated with a deficiency or dysfunction of Copper-transporting ATPase 2, and particularly of Wilson's disease. An AAV vector devised according to the invention significantly reduced urine Cu excretion, and liver Cu content in Wilson's disease mice treated with the vector, while ceruloplasmin activity was significantly restored. On the other hand, the administration of the vector resulted in the normalization of serum transaminases' levels and of liver histology, together with a marked reduction of the inflammatory infiltrate.

The invention discloses a Chinese medicinal composition for resisting hepatic fibrosis and a preparation method and use thereof. The Chinese medicinal composition is prepared from the following Chinese medicinal materials: herb of virgate vormwood, white atractylodes rhizome, prepared aconite root, dried ginger, honey-fried licorice root and cinnamon, according to the mass ratio of 3:6:1.5:1.5:3:1. The Chinese medicinal composition is prepared through subjecting the Chinese medicinal materials, i.e. the herb of virgate vormwood, the white atractylodes rhizome, the prepared aconite root, the dried ginger, the honey-fried licorice root and the cinnamon to water decoction according to a matching ratio, extracting and concentrating. Proved by the pharmacodynamic tests, the Chinese medicinal composition disclosed by the invention can lower the serum transaminase of hepatic fibrosis model mice, can relieve the degree of the liver collagen deposition of the hepatic fibrosis model mice, can improve the hepatic inflammation and the fibrosis pathological change of the hepatic fibrosis model mice, and has the effect of resisting the pathological change of the hepatic fibrosis, so that the Chinese medicinal composition can be used for preparing a pharmaceutical preparation for resisting the hepatic fibrosis.

The present invention discloses a non-alcoholic fatty liver disease prevention and control compound preparation, and the innovation is that: the compound preparation is composed of the following parts by weight of medicinal raw materials: 15 to 60 parts of gynostemma, 15 to 45 parts of astragalus root, 10 to 30 parts of Chinese angelica, 15 to 45 parts of polygonum cuspidatum and 6 to 12 parts of bulbus fritillariae thunbergii. The compound preparation can be prepared into tablets, granules, capsules or oral solutions by conventional methods. Pharmacodynamics shows that the compound preparation has a significant effect of improvement and prevention of fatty degeneration of liver of non-alcoholic fatty liver disease and reduction of serum transaminases.

The invention provides an application of a rosemary compound in a drug for preventing and treating autoimmune hepatitis. The rosemary compound can significantly reduce ConA-induced hepatitis/liver injury, and inhibit the production of inflammatory cytokines, including tumor necrosis factor alpha (TNF-alpha), interleukin 6(IL-6), interferon-gamma(IFN-gamma) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), by reducing serum transaminase ALT/AST level, play an anti-inflammatory role and relieves hepatitis/liver injury. The invention also provides a drug for preventing and treating autoimmune hepatitis, which comprises the rosemary compound.

The invention discloses a crocodile shell extract for treating hepatic fibrosis and application of the crocodile shell extract. The extract is the crocodile shell extract which is prepared by boiling crocodile shells with water, and by extracting, concentrating and drying the liquid. The pharmacodynamic experiment shows that the extract has the effects of reducing serum transaminase of hepatic fibrosis model mice and the deposition degree of liver collagen fiber of the mice, improving liver inflammation and fibrosis pathology change of the mice, preventing and treating liver fibrosis pathology change, and delaying development of chronic liver diseases to liver cirrhosis, and has the potential to be used for developing and preparing medicines for preventing and treating hepatic fibrosis.

The invention discloses a pharmaceutical composition of acetolide acetate and its medical application. The pharmaceutical composition of acetolide acetate provided by the invention contains acetolide acetate and a kind of The obtained natural product compound (I) with a novel structure, alanorelin acetate and compound (I) acting alone can reduce the content of serum transaminase, bilirubin and urea nitrogen in animals with liver damage, alleviate jaundice and renal dysfunction, And can reduce plasma endotoxin content; when alanorelin acetate and compound (I) act in combination, the pharmacological effect is more obvious, can be developed into the medicine for the treatment of acute liver failure, has outstanding substantive characteristics compared with the prior art and significant progress.

The invention discloses application of a traditional Chinese medicine composition in preparation of a drug for preventing and treating novel coronavirus and liver injury. The intervention effect of the traditional Chinese medicine composition on the novel coronavirus (SARS-CoV-2) is screened, it is shown through screening experiments that the provided traditional Chinese medicine composition has acertain resistant effect on the novel coronavirus (SARS-CoV-2), transaminase and bilirubin in the serum of patients with the novel coronavirus (SARS-CoV-2) can be reduced significantly, the liver function can be improved, treatment of the novel coronavirus and the liver injury caused by the novel coronavirus can be assisted, clinical symptoms can be improved significantly, and the cure rate is improved.

The invention relates to a traditional Chinese medicinal composition for improving a liver function. The traditional Chinese medicinal composition is prepared from effective components and pharmaceutically acceptable auxiliaries, and is characterized in that the effective components are prepared from the following raw materials in parts by weight: 20-30 parts of cornus officinalis, 20-30 parts of smoked plum, 15-20 parts of astragalus, 15-20 parts of Chinese angelica, 10-15 parts of abrus cantoniensis hance, and 10-15 parts of rabdosia lophanthide. The traditional Chinese medicinal composition has the effects of nourishing and protecting liver and reducing serum transaminase.

The invention relates to a nucleic acid construct carrying ATP7B protein, an expression vector and a viral particle comprising the nucleic acid construct, and their use for treatment of Wilson's disease and other conditions caused by a deficiency or dysfunction of ATP7B protein. An AAV vector devised according to the invention significantly reduced urine Cu excretion, and liver Cu content in Wilson's disease mice treated with the vector, while ceruloplasmin activity was significantly restored. On the other hand, the administration of the vector resulted in the normalization of serum transaminases levels and of liver histology, together with a marked reduction of the inflammatory infiltrate.

The present invention discloses a Chinese medicine composition for curing chronic hepatitis B and its preparation method. It is made up by using Chinese medicinal materials of phyllanthus, pretty swertia and agrimony through a certain preparation process. Said Chinese medicine composition can be made into various oral preparations.

The invention discloses a pharmaceutical composition for treating early cirrhosis, the pharmaceutical composition comprises astragalus membranaceus, angelica sinensis, safflower carthamus, caulis spatholobi and felwort, the weight ratio of astragalus membranaceus to angelica sinensis to safflower carthamus to caulis spatholobi to felwort is (1-5): (1-2): (1-2): (1-8): (1-4), the preparation method of the pharmaceutical composition is simple, and the pharmaceutical composition can be used for treating early cirrhosis rats and mice. The traditional Chinese medicine composition can reduce the activity of serum transaminase, increase the level of serum albumin, relieve the degree of liver collagen deposition and improve liver injury and pathological changes of early cirrhosis, and has the effects of preventing and treating early cirrhosis lesions.

The invention discloses miR-221/222 and application of its inhibitor in preparation of drugs and detection targets to regulate liver fat deposition, liver fibrosis and liver cell carcinoma; by inhibiting activity of miR-221 and/or miR-222, liver fat infiltration level, liver collagen fiber deposition, plasma cholesterol and serum transaminase are lowered, insulin resistance is improved, and malignant proliferation of liver cells is inhibited.

The invention discloses a drug composition composed of kaempferol, beta-sitosterol and/or tanshinone I and application thereof to preparing alcoholic liver disease treating and preventing drugs. The drug composition is composed of 3-55% of the kaempferol, 10-60% of the beta-sitosterol and 20-80% of the tanshinone I, and an independently applicable drug is composed of 0.5-70% of the kaempferol, 0.03-70% of the beta-sitosterol and 1.5-99% of the tanshinone I. implementing mice alcoholic liver injury models proves the therapeutic effects of the kaempferol, the beta-sitosterol, the tanshinone I and the drug composition on alcoholic liver diseases. Both the drug and the drug composition can effectively reduce liver lesions, particularly, significantly reduce hepatomegaly and weight increment, significantly decrease activity of serum transaminase and intrahepatic triglyceride content, and significantly improve tissue fat accumulation and inflammatory infiltration. The drugs can all prevent and treat alcoholic liver diseases, and also, can independently serve as drugs and be applied to developing corresponding drugs and healthcare products.